FIELD: organic chemistry.
SUBSTANCE: invention relates to a heterocyclic compound of formula (I) or a pharmaceutically acceptable salt thereof, where X is CR7 or N; Z is CR3; R1 is selected from a group consisting of cyano and 5–9 membered heteroaryl, which contains 1–5 heteroatoms independently selected from N, O and S; where 5–9 membered heteroaryl is optionally substituted with 1–2 R8 groups; each of R1a and R1b independently represents hydrogen or halogen; or R1a and R1b together with the carbon atom to which they are bonded are C(O); R2 is C1-C6 alkyl, C3-C7 cycloalkyl or 5–6-member heterocycloalkyl, which contains 1–3 heteroatoms independently selected from NR and O; where each of C3-C7 cycloalkyl and 5–6-member heterocycloalkyl is optionally substituted with 1–2 R9 groups; and where C1-C6 alkyl is optionally substituted with 1–2 R10 groups; R represents C1-C6 alkyl; R3 is selected from a group consisting of hydrogen, deutero, amino, halogen, cyano, C1-C6 alkyl and C1-C6 alkoxy; where each of C1-C6 alkyl and C1-C 6 alkoxy is optionally substituted with 1–3 halogen groups; R4, R5 and R7 independently represent hydrogen or deutero; R6 denotes hydrogen, deutero, halogen or amino; R8 in each case is independently selected from a group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl; where C1-C6 alkyl is optionally substituted with 1–3 halogen, hydroxy or C1-C3 alkoxy groups; R9 at each occurrence is independently selected from the group consisting of halogen, hydroxy, C1-C 6 alkyl and C1-C6 alkoxy, where C1-C6 alkyl and C1-C6 alkoxy are optionally substituted with one to three halogen or cyano groups; and R10 in each case is halogen. Invention also relates to specific compounds, a pharmaceutical composition based on the compound of formula (I) and a method of treating Crohn's disease, Parkinson's disease, dementia with Levy bodies, leprosy, Alzheimer's disease and taupathy.
.
EFFECT: obtaining novel heterocyclic compounds having inhibitory activity of leucine-repeated kinase 2 (LRRK2).
26 cl, 15 tbl, 250 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW IMIDAZO[4,5-c]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | 2018 |
|
RU2773516C2 |
| COMPOUNDS OF THIENOPYRIMIDINE | 2013 |
|
RU2637925C2 |
| N-{2-[4-AMINO-2-(ETHOXYMETHYL)-1H-IMIDAZO-[4,5-c]-QUINOLIN-1-YL]-1,1-DIMETHYLETHYL}-METHANESULFONAMIDE AND PHARMACEUTICAL COMPOSITON BASED ON SAID COMPOUND | 2004 |
|
RU2374246C2 |
| 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATEPSIN K AND S INHIBITORS | 2007 |
|
RU2400482C2 |
| IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONISTS | 2020 |
|
RU2785124C1 |
| IMIDAZOPIRASOTHINES AS PDE1 INHIBITORS | 2016 |
|
RU2712219C2 |
| DERIVATIVES OF CYCLOHEXANE OR TETRAHYDROPYRANE OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, OR HYDRATES, OR SOLVATES OF THESE COMPOUNDS, OR THEIR SALTS, INTERMEDIATE COMPOUNDS FOR THEIR SYNTHESIS AND FUNGICIDE AGENT | 1992 |
|
RU2084439C1 |
| 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS | 2008 |
|
RU2485119C2 |
| HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
| ANALOGUES OF 4H-PYRAZOLO[1,5-A]BENZIMIDAZOLE COMPOUNDS AS PARP INHIBITORS | 2015 |
|
RU2672722C2 |
